GlassScriptPhysician profile
Kenneth J Zwier
NPI 1326036427
$6,575.33
in general payments reported to CMS, 2019-2025
28 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 86% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $423 · 2021: $1,210 · 2022: $857 · 2023: $1,290 · 2024: $985 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $980.38 | 2021-2025 | Azstarys |
| Abbvie INC. | $867.92 | 2021-2025 | Vraylar |
| Tris Pharma INC | $714.31 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $700.53 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $500.06 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.20 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $295.74 | 2019-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $281.98 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $265.42 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $224.94 | 2019-2024 | Spravato |
| Alkermes, INC. | $201.79 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $197.90 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $142.28 | 2019 | |
| Collegium Pharmaceutical, INC. | $140.08 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $110.71 | 2023-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $105.87 | 2019-2025 | Cotempla Xr-Odt, Metadate Cd |
| Shire North American Group INC | $101.10 | 2019 | |
| Idorsia Pharmaceuticals US INC | $82.64 | 2023-2024 | Quviviq |
| Allergan, INC. | $66.73 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $58.66 | 2019-2024 | Relexxii |
| Adlon Therapeutics L.P. | $48.91 | 2019-2021 | |
| Alfasigma USA, INC. | $43.42 | 2021 | |
| Tempus Ai, INC | $28.50 | 2024 | Tempus Pixel |
| Eisai INC. | $24.44 | 2021 | |
| Almatica Pharma LLC | $22.52 | 2021 | |
| Avion Pharmaceuticals | $21.88 | 2023 | Methylphenidate Hydrochloride |
| Neurocrine Biosciences, INC. | $20.89 | 2023 | Ingrezza |
| Harmony Biosciences LLC | $20.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Zwier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.